Investor relations

Skip to content
Skip to navigation
Skip to footer

AstraZeneca Q1 2022 results - Webcast and investor information

Read more

Key facts

Go to page

Fact sheet

Open PDF

Contacts

Jump to Contacts

Latest aide memoire

Open PDF

collaboration image

As we look ahead to pursuing our science-led strategy in the years up to 2025, we have identified three priority areas. We want to ensure that we broaden access to healthcare, minimise our environmental footprint, and ensure ethics and transparency underpin everything we do.

Emerging Markets are key to the ongoing pipeline- and sales-driven transformation of AstraZeneca. Over the past years, our global sales base has changed from having most of sales coming from what we now call ‘Other’ medicines to our current setup where our business is focused on three main therapy areas: Oncology, New Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. In these therapy areas, Emerging Markets now outperform the rest of the world.

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

It takes passion, energy and knowledge to enable us to put science at the heart of everything we do. Visit the 'What science can do' section of our website to read about our exciting work in stories from our people and partners.

This data might not be the latest available

Share calculator

Upcoming events

16 May

Virtual conference, Guggenheim, Synthetic Lethality Day [management]

Add to Calendar

6 Jun

Meet AZN management: American Society of Clinical Oncology 2022 Annual Meeting

Add to Calendar

View all events

Annual Reports

2021

PDF 13,176KB

View online summary

2020

PDF 12,602KB

View online summary

2019

PDF 11,262KB

View online summary

2018

PDF 7,964KB

View online summary

2017

PDF 14,751KB

View online summary

2016

PDF 18,551KB

View online summary

2015

PDF 10,487KB

View online summary

2006-2014

PDF 5,660KB

PDF 4,097KB

PDF 102KB

PDF 4,810KB

PDF 4,031KB

PDF 11,072KB

PDF 3,986KB

PDF 13,076KB

PDF 6,024KB

PDF 4,864KB

PDF 8,237KB

PDF 5,824KB

PDF 3,420KB

PDF 7,122KB

PDF 1,878KB

PDF 3,561KB

PDF 5,115KB

PDF 1,740KB

PDF 1,927KB

Annual reports archive

Investor enquiries

Main Contacts

Chris Sheldon

Chris Sheldon

Head of Investor Relations

+44 203 749 5712

Oncology

Josie Afolabi

Oncology

+44 203 749 5631

Tom Waldron

Tom Waldron

Oncology

+44 122 334 4734

Christer Gruvris

Christer Gruvris

BioPharmaceuticals (Cardiovascular, Renal and Metabolism), Finance & Fixed Income

+44 203 749 5711

Morgan Sanford

Morgan Sanford

BioPharmaceuticals (Respiratory & Immunology), Rare Disease

+1 203 856 0420

Philip Sparks

Philip Sparks

BioPharmaceuticals (Vaccines & Immune Therapies), Other medicines

+44 122 334 4706

Lauren Swales

Lauren Swales

Environment, Social and Governance

+44 122 334 4772

US general enquiries

+1 301 398 3251